Free Trial
NASDAQ:AVIR

Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis

Atea Pharmaceuticals logo
$3.14 -0.17 (-5.00%)
Closing price 03:59 PM Eastern
Extended Trading
$3.14 +0.01 (+0.16%)
As of 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Atea Pharmaceuticals Stock (NASDAQ:AVIR)

Key Stats

Today's Range
$3.10
$3.29
50-Day Range
$3.15
$3.90
52-Week Range
$2.45
$4.14
Volume
136,566 shs
Average Volume
371,902 shs
Market Capitalization
$248.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Moderate Buy

Company Overview

Atea Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

AVIR MarketRank™: 

Atea Pharmaceuticals scored higher than 42% of companies evaluated by MarketBeat, and ranked 742nd out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Atea Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Upside Potential

    Atea Pharmaceuticals has a consensus price target of $6.00, representing about 90.2% upside from its current price of $3.16.

  • Amount of Analyst Coverage

    Atea Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Atea Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Atea Pharmaceuticals are expected to grow in the coming year, from ($2.01) to ($1.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Atea Pharmaceuticals is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Atea Pharmaceuticals is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Atea Pharmaceuticals has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Atea Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    9.11% of the float of Atea Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Atea Pharmaceuticals has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Atea Pharmaceuticals has recently increased by 19.84%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Atea Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Atea Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.11% of the float of Atea Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Atea Pharmaceuticals has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Atea Pharmaceuticals has recently increased by 19.84%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Atea Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Atea Pharmaceuticals this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for AVIR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Atea Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Atea Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    18.10% of the stock of Atea Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    86.67% of the stock of Atea Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Atea Pharmaceuticals' insider trading history.
Receive AVIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AVIR Stock News Headlines

Forget NVDA. Put $1,000 into this stock now
A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW kind of AI stock.tc pixel
Atea (AVIR) Q2 Loss Narrows 8%
See More Headlines

AVIR Stock Analysis - Frequently Asked Questions

Atea Pharmaceuticals' stock was trading at $3.35 at the start of the year. Since then, AVIR shares have decreased by 5.8% and is now trading at $3.1550.

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) posted its quarterly earnings data on Thursday, August, 7th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.02.
Read the conference call transcript
.

Atea Pharmaceuticals (AVIR) raised $253 million in an initial public offering (IPO) on Friday, October 30th 2020. The company issued 11,000,000 shares at $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair served as the underwriters for the IPO.

Atea Pharmaceuticals' top institutional shareholders include Geode Capital Management LLC (2.25%), JPMorgan Chase & Co. (0.82%), Hsbc Holdings PLC (0.25%) and American Century Companies Inc. (0.22%). Insiders that own company stock include Jean-Pierre Sommadossi, Andrea Corcoran, Franklin M Berger, Bruce Polsky and Wayne Foster.
View institutional ownership trends
.

Shares of AVIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Atea Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), PayPal (PYPL) and Broadcom (AVGO).

Company Calendar

Last Earnings
8/07/2025
Today
9/12/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AVIR
CIK
1593899
Fax
N/A
Employees
70
Year Founded
N/A

Price Target and Rating

High Price Target
$6.00
Low Price Target
$6.00
Potential Upside/Downside
+91.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.61)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$168.38 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-32.55%
Return on Assets
-30.47%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
19.17
Quick Ratio
19.17

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.20 per share
Price / Book
0.60

Miscellaneous

Outstanding Shares
79,360,000
Free Float
64,994,000
Market Cap
$248.79 million
Optionable
Optionable
Beta
0.24

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:AVIR) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners